1. Home
  2. Live Updates
  3. Olgensma

Live Breaking News & Updates on Olgensma

Stay informed with the latest breaking news from Olgensma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Olgensma and stay connected to the pulse of your community

All about Zolgensma: the Rs 17 crore injection for spinal muscular atrophy

A staggering Rs 17 crore for a single jab! That’s the cost of one Zolgensma injection used for children under two suffering from spinal muscular atrophy (SMA), the...

Switzerland , New-delhi , Delhi , India , Hyderabad , Andhra-pradesh , Karnataka , Swiss , Vibhu-kawatra , Risdaplam-evrysdi , Sheffali-gulati , N-varsha-monica-reddy

La Plata family sees benefits from new SMA treatment

Between 1 in 6,000 and 1 in 10,000 babies are born with spinal muscular atrophy each year.

North-point-high-school , Maryland , United-states , District-of-columbia , Piccowaxen-middle-school , American , Aaron , Point-high-school , American-congress , Southern-maryland , Southern-maryland-news

Bristol Myers Squibb acquires US viral vector production facility from Novartis

Bristol Myers Squibb will boost its cell therapy manufacturing network with in-house viral vector production thanks to the acquisition of Novartis’ Libertyville, Illinois facility.

Libertyville , New-jersey , United-states , North-carolina , Netherlands , Washington , Massachusetts , Lynelle-hoch , Bristol-myers-squibb , Karin-shanahan , Novartis , Myers-squibb

Imported drugs for treating rare diseases now exempt from basic customs duty: What this means

On March 28, Congress leader and MP Shashi Tharoor shared the story of a young couple who had approached him for exemption of duty on a drug they imported for their young daughter suffering from cancer.

Mumbai , Maharashtra , India , Thiruvananthapuram , Kerala , Shashi-tharoor , Vivek-johri , Sernya-bhutia , Rajasthan-right-to-health , Finance-minister-nirmala-sitharaman , Mrs-sitharaman , Indirect-taxes

Novartis shares Zolgensma long-term data demonstrating

Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll...

London , City-of , United-kingdom , United-states , Switzerland , America , Sitra-tauscher-wisniewski , Intrathecal-onasemnogene-abeparvovec , Richard-jarvis , Isabella-zinck , Michael-meo , Satoshi-sugimoto

Novartis Pharma AG: Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort

London , City-of , United-kingdom , United-states , Switzerland , America , Sitra-tauscher-wisniewski , Intrathecal-onasemnogene-abeparvovec , Richard-jarvis , Isabella-zinck , Michael-meo , Satoshi-sugimoto

Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing

BASEL (dpa-AFX) - Novartis AG (NVS) Monday presented new long-term data of Zolgensma (onasemnogene abeparvovec), the only approved one-time gene therapy for the treatment of spinal muscular atrophy

Sitra-tauscher-wisniewski , Muscular-dystrophy-association , Clinical-development-analytics , More-such-health-news , Novartis , Long-term-follow-up , Dystrophy-association , Scientific-conference , Vice-president-clinical-development , Novartis-gene-therapies , Diese-gold-aktie

Cell and Gene Therapies Push Payers to New Strategies to Assess Outcomes

Cell and gene therapies are offering patients potentially curative treatments for a growing scope of diseases. Insurance companies are trying to figure out how to pay for them. Industry consultants speaking at the HLTH conference offered some strategies they see payers taking to these new therapies.

United-states , American , Nico-economides , Novartis-zolgensma , Raymond-brown , Oliver-wyman , Las-vegas , North-american , Biomarin-pharmaceutical , Bluebird-bio , Weight-loss

Novartis warns of two patients deaths after dosing with gene therapy Zolgensma

The two deaths reported following treatment with Novartis’s Zolgensma mark the first fatal cases of acute liver failure associated with the gene therapy. Liver complications are a known side effect risk of Zolgensma and other genetic medicines that are delivered by engineered viruses.

Russia , Kazakhstan , Astellas-pharma , Novartis , Weight-loss , Besity , Verweight , Diabetes , Massachusetts , Medical-devices , Obesity , Startups

NOVARTIS REPORTS TWO CHILDREN DIED FROM ACUTE LIVER FAILURE AFTE…

NOVARTIS REPORTS TWO CHILDREN DIED FROM ACUTE LIVER FAILURE AFTER TREATMENT WITH ITS ZOLGENSMA GENE THERAPY - STAT NEWS
... | August 11, 2022

Novartis-ag-stock-exchange , Ews , Nformation , Ress-release , Ovartis , Eports , Wo , Hildren , Ied , Rom , Cute